Article
Bridging phenotype and function in bladder cancer using immuno-competent organoids and ex vivo drug screening.
Journal of experimental & clinical cancer research : CR - 1 Apr 2026
Frascolla Carlotta, Mastroianni Riccardo, Macedo-Silva Catarina, De Menna Marta, Orlandi Giulia, Covino Daniela Angela, Minoli Martina, Radic Martina, La Manna Federico, Pulito Claudio, Vaccarella Sebastiano, Goeman Frauke, Ciuffreda Ludovica, Allegretti Matteo, Seiler Roland, Kiss Bernhard, De Pascale Valentina, Runci Federica, Calabrò Fabio, Vinik Yaron, Lev Sima, Strano Sabrina, Fanciulli Maurizio, Arteni Brindusa Ana Maria, Di Martino Simona, Russo Andrea, Donzelli Sara, Kruithof-de Julio Marianna, Blandino Giovanni, Simone Giuseppe
Abstract excerpt
BACKGROUND: Bladder cancer (BLC) remains a clinically challenging malignancy due to its pronounced inter- and intra-patient heterogeneity, which contributes to therapeutic resistance and poor clinical outcomes. Capturing and modeling this complexity is essential for the development of effective, personalized therapeutic strategies. METHODS: To investigate molecularly and functionally BLC heterogeneity, this study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.